Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 33Lenalidomide 14pomalidomide 12daratumumab 12Bortezomib 12venetoclax 7Cyclophosphamide 7isatuximab 6Therapeutics 6trametinib 4carfilzomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3fludarabine 3dabrafenib 3Vemurafenib 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Drug Therapy 3Denosumab 3Ciprofloxacin 3Calcium Dobesilate 3ridaforolimus 2pembrolizumab 2molibresib 2liposomal amphotericin B 2fludarabine phosphate 2cobimetinib 2afuresertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Ranitidine × Plasma cell × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡